Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.

Peter C TaylorThomas BieberRieke AltenTorsten WitteJames GallowayWalter DeberdtMaher IssaEwa HaladyjInmaculada De La TorreSusanne GrondAndreas Wollenberg

Published in: Advances in therapy (2023)

Populations with low risk have low incidence of the examined JAK inhibitor-related AESI. In the dermatologic indications, incidence is also low for patients at risk. Considering individual disease burden, risk factors, and response to treatment is relevant to make informed decisions for individual patients treated with baricitinib.

Keyphrases

risk factors
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
study protocol
open label
big data
clinical trial
patient reported outcomes
replacement therapy